BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23849895)

  • 1. ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma.
    Johnson H; Zhou M; Osunkoya AO
    Hum Pathol; 2013 Oct; 44(10):2241-6. PubMed ID: 23849895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN Expression in Mucinous Prostatic Adenocarcinoma, Prostatic Adenocarcinoma With Mucinous Features, and Adjacent Conventional Prostatic Adenocarcinoma: A Multi-institutional Study of 92 Cases.
    Bertsch EC; Magi-Galluzzi C; Cheng L; Osunkoya AO
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):225-230. PubMed ID: 29621096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical evaluation of TMPRSS2-ERG gene fusion in adenosis of the prostate.
    Green WM; Hicks JL; De Marzo A; Illei PP; Epstein JI
    Hum Pathol; 2013 Sep; 44(9):1895-901. PubMed ID: 23664537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
    Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
    Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy.
    Osunkoya AO; Adsay NV; Cohen C; Epstein JI; Smith SL
    Mod Pathol; 2008 Jul; 21(7):789-94. PubMed ID: 18487999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
    Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
    J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.
    Kimura T; Furusato B; Miki J; Yamamoto T; Hayashi N; Takahashi H; Kamata Y; van Leenders GJ; Visakorpi T; Egawa S
    Pathol Int; 2012 Nov; 62(11):742-8. PubMed ID: 23121605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
    Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
    Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.
    Yaskiv O; Zhang X; Simmerman K; Daly T; He H; Falzarano S; Chen L; Magi-Galluzzi C; Zhou M
    Am J Surg Pathol; 2011 Jul; 35(7):1062-8. PubMed ID: 21623182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients.
    Furusato B; van Leenders GJ; Trapman J; Kimura T; Egawa S; Takahashi H; Furusato M; Visakorpi T; Hano H
    Pathol Int; 2011 Jul; 61(7):409-14. PubMed ID: 21707844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERG expression in prostate cancer: the prognostic paradox.
    Taris M; Irani J; Blanchet P; Multigner L; Cathelineau X; Fromont G
    Prostate; 2014 Nov; 74(15):1481-7. PubMed ID: 25175352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.
    Schneider TM; Osunkoya AO
    Mod Pathol; 2014 Aug; 27(8):1174-8. PubMed ID: 24406865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
    Lippolis G; Edsjö A; Stenman UH; Bjartell A
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucin-producing tumors and tumor-like lesions involving the prostate: a comprehensive review.
    Bohman KD; Osunkoya AO
    Adv Anat Pathol; 2012 Nov; 19(6):374-87. PubMed ID: 23060063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN.
    He H; Osunkoya AO; Carver P; Falzarano S; Klein E; Magi-Galluzzi C; Zhou M
    BJU Int; 2012 Dec; 110(11 Pt B):E751-5. PubMed ID: 23046279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.